Optimus Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir Conducted in India
Hyderabad (Telangana) [India], July 21: Optimus Pharma on Sunday submitted the interim result of Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild Covid-19 patients. With an acute shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.
In a statement, the MD and Chairman Dr. D Srinivasa Reddy had declared that Optimus pharma has internally developed the active pharmaceutical ingredient (API) and the formulations for the product and had obtained approval for conducting Phase 3 Clinical Trial.
As per the clinical trial protocol approved, 1218 subjects with mild COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with the standard of care, or standard of care alone. The treatment duration is a maximum of 05 days and the total study duration will be a maximum of 28 days from randomisation.
“Optimus is all geared to immediately begin manufacturing of Molnupiravir for COVID-19 patients in India. The interim results on 353 patients have shown promising results of Molnupiravir. The drug has been successful in reducing viral load effectively with RT-PCR negativity achieved 78.3 % in the test arm compared to 48.4% in the standard of care arm on Day 5. Day 10 and Day 14 of the treatment duration have also given excellent results wherein the remaining patients have successfully achieved RT-PCR negativity. The trial has also revealed clinical improvement in a significantly high proportion of patient’s health. The safety of the drug has also been established with no observed side effects, co-morbidity, or morbidity observed during and after the treatment duration,” Chairman & Managing Director – Dr. D Srinivasa Reddy said.
Optimus has approached the Drugs Controller General of India (DCGI) to seek Emergency Use Authorization for Molnupiravir in India.
Optimus Pharma is committed to serve the nation and fight back the pandemic to restore normalcy in the lives of people affected by COVID-19 at the earliest. With the cooperation of the government and our stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, we hope to deliver the product in India by leveraging our solid distribution strength across the country.
16 thoughts on “Optimus Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir Conducted in India”
There is definately a great deal to know about this topic.
I really like all of the points you’ve made.
Thank you for the good writeup. It in fact was a amusement account it.
Look advanced to far added agreeable from you! However, how
can we communicate?
I visited many blogs however the audio feature for audio songs current at
this site is in fact wonderful.
Excellent site you have here but I was curious about if you knew
of any forums that cover the same topics discussed in this article?
I’d really love to be a part of community where I can get feedback from other experienced individuals that share
the same interest. If you have any suggestions, please let me know.
I’m really enjoying the theme/design of your site. Do you ever run into any internet browser compatibility
problems? A small number of my blog audience have complained about my website not operating correctly in Explorer but looks great in Chrome.
Do you have any solutions to help fix this problem?
I’ve been surfing online greater than 3 hours nowadays,
yet I never found any fascinating article like yours. It
is pretty value sufficient for me. In my view, if all web owners and bloggers
made just right content as you probably did, the net will be much more useful than ever before.
Your style is really unique compared to other people I’ve read stuff from.
Many thanks for posting when you’ve got the opportunity,
Guess I will just bookmark this blog.
Woah! I’m really loving the template/theme of this site.
It’s simple, yet effective. A lot of times it’s very difficult to get that “perfect balance” between user friendliness and appearance.
I must say you’ve done a amazing job with this. In addition, the blog loads extremely
fast for me on Internet explorer. Excellent Blog!
I have read so many articles regarding the blogger lovers but this
article is actually a nice article, keep it up.
Wow! This blog looks just like my old one! It’s on a completely different subject but it has pretty much
the same layout and design. Outstanding choice of colors!
Great site you have here but I was wanting to know if you knew of any community forums that cover
the same topics discussed here? I’d really love to be a part of online community where I can get opinions from other experienced people that share the
same interest. If you have any suggestions, please let
me know. Many thanks!
Link exchange is nothing else however it is only placing the other
person’s weblog link on your page at appropriate place and other person will also do same in support of you.
I got this web page from my buddy who informed me on the topic of this website and now this time I
am visiting this website and reading very informative articles
or reviews at this place.
I’m curious to find out what blog platform you happen to be utilizing?
I’m experiencing some minor security issues with my latest
site and I would like to find something more safe. Do you have any solutions?
Link exchange is nothing else except it is only placing
the other person’s web site link on your page at suitable
place and other person will also do same in support of
Thanks for finally writing about > Optimus Announces Interim Clinical Results from
Phase III Clinical Trials of Molnupiravir Conducted in India –
Financial Telegraph special